Press Release: YM BioSciences Announces President And CEO To Leave Position

YM BioSciences Announces President And CEO To Leave Position Effective Immediately MISSISSAUGA, ON, Feb. 12 - YM BioSciences Inc., an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that Gail Schulze, President, YM BioSciences, and CEO, YM BioSciences USA, Inc., and John E. Bennett, Vice President, Corporate Development, YM BioSciences USA, Inc., have left their positions effective immediately. Gail Schulze will remain a director of the Company. "In light of the recent termination of the tesmilifene pivotal trial, we recognized the need to rapidly re-focus Company resources, including our organizational structure, on accelerating the clinical development of our promising nimotuzumab and AeroLEF(TM) programs and to reduce expenditures and the size of management overhead," said David Allan, Chairman and CEO of YM BioSciences. "As key members of the U.S. management team assembled through our acquisition of Eximias, Gail and John brought extensive commercialization and partnering expertise to YM BioSciences at a critical juncture and their roles in our preparations for the NDA filing, market development and product launch of tesmilifene were significant. Along with the Board of Directors of YM BioSciences, I would like to thank them for the contributions they have made during their time at YM BioSciences." Mr. Allan added, "As we realign our strategy, we continue to evaluate our current resources against our revised business requirements in order to determine whether additional changes to the management team are needed." About YM BioSciences YM BioSciences, Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company has two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF(TM), a unique, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain. This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.